Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2023 7
2024 10
2025 38
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.
Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Hendershot CS, et al. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. doi: 10.1001/jamapsychiatry.2024.4789. JAMA Psychiatry. 2025. PMID: 39937469 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD). ...CONCLUSIONS AND RELEVANCE: These findings provide initial prospective evidence that low-d …
OBJECTIVE: To evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with …
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Lähteenvuo M, et al. JAMA Psychiatry. 2025 Jan 1;82(1):94-98. doi: 10.1001/jamapsychiatry.2024.3599. JAMA Psychiatry. 2025. PMID: 39535805 Free PMC article.
IMPORTANCE: Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption. OBJECTIVE: To test whether the risk of hospitalization due to alcohol use disorder …
IMPORTANCE: Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, m …
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Wang W, et al. Nat Commun. 2024 May 28;15(1):4548. doi: 10.1038/s41467-024-48780-6. Nat Commun. 2024. PMID: 38806481 Free PMC article.
Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders. In this retrospective cohort study of electronic health records of 83,825 patients with obesity, we show that …
Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for …
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.
Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. Chuong V, et al. JCI Insight. 2023 Jun 22;8(12):e170671. doi: 10.1172/jci.insight.170671. JCI Insight. 2023. PMID: 37192005 Free PMC article.
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD). Here, we examined the effects of semaglutide …
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 …
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.
Quddos F, Hubshman Z, Tegge A, Sane D, Marti E, Kablinger AS, Gatchalian KM, Kelly AL, DiFeliceantonio AG, Bickel WK. Quddos F, et al. Sci Rep. 2023 Nov 28;13(1):20998. doi: 10.1038/s41598-023-48267-2. Sci Rep. 2023. PMID: 38017205 Free PMC article.
Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown …
Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP …
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Klausen MK, Justesen SK, Pedersen JN, Rasmussen L, Jensen A, Jensen ME, Knorr UB, Bergmann ML, Holst JJ, Hartmann B, Koob GF, Benveniste H, Volkow ND, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. Lancet. 2026 May 2;407(10540):1687-1698. doi: 10.1016/S0140-6736(26)00305-3. Lancet. 2026. PMID: 42070571 Free article. Clinical Trial.
BACKGROUND: Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. Preclinical and initial human studies indicate that the GLP-1 receptor agonist semaglutide might reduce alc …
BACKGROUND: Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new ther …
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
Aranäs C, Edvardsson CE, Shevchouk OT, Zhang Q, Witley S, Blid Sköldheden S, Zentveld L, Vallöf D, Tufvesson-Alm M, Jerlhag E. Aranäs C, et al. EBioMedicine. 2023 Jul;93:104642. doi: 10.1016/j.ebiom.2023.104642. Epub 2023 Jun 7. EBioMedicine. 2023. PMID: 37295046 Free PMC article.
BACKGROUND: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD). However, the probability of low semaglutide doses, an agonist with highe …
BACKGROUND: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight pa …
Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.
Klausen MK, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. Basic Clin Pharmacol Toxicol. 2025 Mar;136(3):e70004. doi: 10.1111/bcpt.70004. Basic Clin Pharmacol Toxicol. 2025. PMID: 39891507 Free PMC article. Review.
In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) approved for treating Type 2 diabetes and obesity have caught much attention. ...Several clinical trials are ongoing, exa …
In the search for novel treatment strategies for alcohol use disorder (AUD), glucagon-like peptide-1 (GLP-1) receptor a …
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
Klausen MK, Kuzey T, Pedersen JN, Justesen SK, Rasmussen L, Knorr UB, Mason G, Ekstrøm CT, Holst JJ, Koob G, Benveniste H, Volkow ND, Knudsen GM, Vilsbøll T, Fink-Jensen A. Klausen MK, et al. BMJ Open. 2025 Jan 8;15(1):e086454. doi: 10.1136/bmjopen-2024-086454. BMJ Open. 2025. PMID: 39779270 Free PMC article.
INTRODUCTION: Alcohol use disorder (AUD) is a massive burden for the individual, relatives and society. ...The primary endpoint is the reduction in heavy drinking days, defined as days with excess consumption of 48/60 g of alcohol per day (women and me …
INTRODUCTION: Alcohol use disorder (AUD) is a massive burden for the individual, relatives and society. ...The primary …
Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.
Liu T, Shi F, Guo Z, Li H, Qin D. Liu T, et al. Pharmacopsychiatry. 2025 Nov;58(6):255-262. doi: 10.1055/a-2550-6470. Epub 2025 Apr 14. Pharmacopsychiatry. 2025. PMID: 40228539 Review.
Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. ...Studies have shown that it significantly reduces alcohol consumption and relapse of alcohol addiction in rats, suggesting …
Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. …
67 results